{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:30:09Z","timestamp":1787617809860,"version":"build-2736575974"},"reference-count":69,"publisher":"BMJ","funder":[{"name":"National\/Tianjin Key Clinical Specialty Construction Project and National Natural Science Foundation of China","award":["81800165"],"award-info":[{"award-number":["81800165"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2026,4,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) have been widely used for over 35 years. However, in recent decades, numerous adverse drug reactions (ADRs) have been reported, with evidence often inconsistent and heterogeneous across studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct an overview of systematic reviews\/meta-analyses (SR\/MAs) to provide a contemporary review of the evidence for the safety of PPIs in patients using them for treating or prophylaxis, to summarise the outcome data, assess the methodological quality and rate the certainty of the evidence and to provide references for clinical decision-making and the subsequent formulation of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an overview of reviews following the Preferred Reporting Items for Overviews of Reviews guidelines. We identified SR\/MAs regarding PPI safety through a search of multiple databases, including the China National Knowledge Infrastructure, Chinese Science and Technology Journal Database and Wanfang Database (WanFang) on 6 December 2025 as well as Embase, PubMed and the Cochrane Library database on 7 December 2025. The participants were human populations who had been administered PPIs; the intervention groups used PPI-based regimens and the control group received different PPI regimens, no-PPIs, H2-receptor antagonists (H2RAs), potassium-competitive acid blockers (P-CAB) or placebo; the outcomes mainly included the specific ADRs associated with PPI use. We used the A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool to assess the methodological quality of the included SR\/MAs and employed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to evaluate the quality of evidence for the reported outcomes. The focus of the data presentation was descriptive, featuring detailed tabular presentations of characteristics and results at both the review level and the primary studies level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results<\/jats:title>\n                    <jats:p>\n                      A total of 940 studies were retrieved from various databases according to the search strategies. After eliminating duplicates and the screening process, 36\u2009SR\/MAs were finally included. Overall, there was a slight overlap (corrected covered area, CCA of 0.91%) in 483 primary studies included in the 36\u2009SR\/MAs. AMSTAR-2 evaluation results showed that 34\u2009SR\/MAs were of low quality, and the other two were of critically low quality. The GRADE evaluation results indicated that the certainty of evidence for all outcomes was\n                      <jats:italic>low<\/jats:italic>\n                      or\n                      <jats:italic>very low<\/jats:italic>\n                      . The use of PPIs might be associated with an increased risk of acute kidney injury (AKI) (relative risk (RR) 1.75, 95%\u2009CI 1.40 to 2.19), chronic kidney disease (CKD) (RR 1.35, 95%\u2009CI 1.15 to 1.56), gastric cancers (GC) (RR 1.67, 95%\u2009CI 1.39 to 2.00) and community-acquired pneumonia (CAP) (OR 1.37, 95%\u2009CI 1.22 to 1.53). PPI therapy was associated with a higher recurrence rate of\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection (CDI) (24% vs 18%)\u2009and might increase CDI risk in renal transplant recipients (RR 2.33, 95%\u2009CI 1.07 to 5.07). The use of PPIs might heighten the risk of fractures in young patients (aged &lt;29 years) (RR 1.20, 95%\u2009CI 1.12 to 1.29). PPI therapy was also linked to hypomagnesaemia in haemodialysis patients (1\/36, 2.78%) and renal transplant recipients (1\/36, 2.78%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This overview evaluates the safety profile of PPIs, noting associated risks including renal impairment, GC, fractures and infections. Most evidence comes from observational studies, resulting in\n                      <jats:italic>low<\/jats:italic>\n                      or\n                      <jats:italic>very low<\/jats:italic>\n                      certainty evidence that limits definitive causal conclusions. Clinicians and pharmacists may consider greater vigilance with PPI use, and these ADRs may not require de-escalation but de-implementation when inadequate (eg, long-term use or special group use). Future research should focus on high-quality prospective studies and investigate underlying mechanisms to better establish causality and quantify risks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251059575.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjebm-2025-114134","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:25:19Z","timestamp":1781594719000},"page":"bmjebm-2025-114134","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6077-891X","authenticated-orcid":false,"given":"Chao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-7127","authenticated-orcid":false,"given":"Huier","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1088-4654","authenticated-orcid":false,"given":"Cheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"First Central Clinical College, Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-1910","authenticated-orcid":false,"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0226-9874","authenticated-orcid":false,"given":"Yinpeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6391-6799","authenticated-orcid":false,"given":"Yude","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1764-9412","authenticated-orcid":false,"given":"Guodong","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-1422","authenticated-orcid":false,"given":"Xinran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0938-7612","authenticated-orcid":false,"given":"Ting","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangyuan Central Hospital, Guangyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9296-2819","authenticated-orcid":false,"given":"Fan","family":"He","sequence":"additional","affiliation":[{"name":"Tianjin Medical Service Evaluation & Guidance Center, Tianjin Medical Service Evaluation & Guidance Center, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8330-2745","authenticated-orcid":false,"given":"Qianqian","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9929-7722","authenticated-orcid":false,"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4712-1554","authenticated-orcid":false,"given":"Mei","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Kidney Transplantion, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3017-9335","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-7002","authenticated-orcid":false,"given":"Yishan","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061600251266000_bmjebm-2025-114134v1.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03534-z"},{"key":"2026061600251266000_bmjebm-2025-114134v1.2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"2026061600251266000_bmjebm-2025-114134v1.3","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/pds.5676","article-title":"Trends in use of proton pump inhibitors among adults in the United States from 1999 to 2018","volume":"32","author":"Bergin","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026061600251266000_bmjebm-2025-114134v1.4","unstructured":"Zhuang JX , Cui JG , Dou YF , et al . Analysis of proton pump inhibitor usage in 129 hospitals across 9 cities in China from 2018 to 2022. Clinical Medication Journal 2024;3969. doi:10.3969\/j.issn.1672-3384.2024.Z1.014"},{"key":"2026061600251266000_bmjebm-2025-114134v1.5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.therap.2020.06.019","article-title":"Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations","volume":"76","author":"Koyyada","year":"2021","journal-title":"Therapie"},{"key":"2026061600251266000_bmjebm-2025-114134v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0532-9"},{"key":"2026061600251266000_bmjebm-2025-114134v1.7","doi-asserted-by":"crossref","unstructured":"H\u00e1lfd\u00e1narson \u00d3\u00d6 , Potteg\u00e5rd A , Bj\u00f6rnsson ES , et al . Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018;11. doi:10.1177\/1756284818777943","DOI":"10.1177\/1756284818777943"},{"key":"2026061600251266000_bmjebm-2025-114134v1.8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00228-019-02753-7","article-title":"Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies","volume":"76","author":"Zhang","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7704\/kjhugr.2020.0057","article-title":"Proton pump inhibitors and the risk of dementia: a systematic review and meta-analysis","volume":"21","author":"Yoon","year":"2021","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"key":"2026061600251266000_bmjebm-2025-114134v1.10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jcpt.13589","article-title":"Comparing safety of proton\u2010pump inhibitors versus H2\u2010receptor antagonists in kidney transplant recipients: a systematic review and meta\u2010analysis","volume":"47","author":"Mohammadi","year":"2022","journal-title":"Clinical Pharmacy Therapeu"},{"key":"2026061600251266000_bmjebm-2025-114134v1.11","unstructured":"Lang L . Evaluation of the efficacy of proton pump inhibitors in the treatment of gastroesophageal reflux-induced asthma and their safety in kidney transplant patients. Tongfang Knowledge Network (Beijing) Technology Co., Ltd, 2020."},{"key":"2026061600251266000_bmjebm-2025-114134v1.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jrsm.1557","article-title":"Graphical representation of overlap for overviews: GROOVE tool","volume":"13","author":"P\u00e9rez-Bracchiglione","year":"2022","journal-title":"Res Synth Methods"},{"key":"2026061600251266000_bmjebm-2025-114134v1.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.09.016"},{"key":"2026061600251266000_bmjebm-2025-114134v1.16","doi-asserted-by":"crossref","unstructured":"Sterne JA , Hern\u00e1n MA , Reeves BC , et al . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;i4919. doi:10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"2026061600251266000_bmjebm-2025-114134v1.17","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191610299","article-title":"Altered food behavior and cancer: a systematic review of the literature","volume":"19","author":"Nucci","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026061600251266000_bmjebm-2025-114134v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2026061600251266000_bmjebm-2025-114134v1.19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072467","article-title":"A meta-analysis of proton pump inhibitor use and the risk of acute kidney injury: geographical differences and associated factors","volume":"12","author":"Han","year":"2023","journal-title":"J Clin Med"},{"key":"2026061600251266000_bmjebm-2025-114134v1.21","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3390\/jcm12062262","article-title":"Proton pump inhibitors and risk of chronic kidney disease: evidence from observational studies","volume":"12","author":"Wu","year":"2023","journal-title":"JCM"},{"key":"2026061600251266000_bmjebm-2025-114134v1.22","doi-asserted-by":"crossref","unstructured":"Vengrus CS , Delfino VD , Bignardi PR . Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol 2021;73. doi:10.23736\/S2724-6051.21.04116-3","DOI":"10.23736\/S2724-6051.21.04116-3"},{"key":"2026061600251266000_bmjebm-2025-114134v1.23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5056\/jnm24145","article-title":"Association of proton pump inhibitor use with gastric cancer in regions with high prevalence of gastric cancer: systematic review and meta-analysis","volume":"31","author":"Kang","year":"2025","journal-title":"J Neurogastroenterol Motil"},{"key":"2026061600251266000_bmjebm-2025-114134v1.24","article-title":"A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine (Abingdon)"},{"key":"2026061600251266000_bmjebm-2025-114134v1.25","doi-asserted-by":"crossref","unstructured":"Tran TH , Myung SK , Trinh TTK . Proton pump inhibitors and risk of gastrointestinal cancer: a meta\u2011analysis of cohort studies. Oncol Lett 2023;27. doi:10.3892\/ol.2023.14161","DOI":"10.3892\/ol.2023.14161"},{"key":"2026061600251266000_bmjebm-2025-114134v1.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08018-9"},{"key":"2026061600251266000_bmjebm-2025-114134v1.27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032228","article-title":"Use of proton pump inhibitors for the risk of gastric cancer","volume":"101","author":"Gao","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026061600251266000_bmjebm-2025-114134v1.28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.07.030","article-title":"Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers","volume":"156","author":"Zeng","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026061600251266000_bmjebm-2025-114134v1.29","article-title":"Whether long-term use of proton pump inhibitor increases the risk of precancerous lesions in the stomach: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Lv","year":"2023","journal-title":"Medicine (Abingdon)"},{"key":"2026061600251266000_bmjebm-2025-114134v1.30","doi-asserted-by":"crossref","unstructured":"Zhou W , Chen X , Fan Q , et al . Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer: a systematic review and meta-analysis. Front Pharmacol 2022;13. doi:10.3389\/fphar.2022.979215","DOI":"10.3389\/fphar.2022.979215"},{"key":"2026061600251266000_bmjebm-2025-114134v1.31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082220","article-title":"Does the use of proton pump inhibitors increase the risk of pancreatic cancer? A systematic review and meta-analysis of epidemiologic studies","volume":"12","author":"Hong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026061600251266000_bmjebm-2025-114134v1.32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00228-020-02854-8","article-title":"Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis","volume":"76","author":"Song","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12072-019-10010-3","article-title":"Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Hepatol Int"},{"key":"2026061600251266000_bmjebm-2025-114134v1.34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10620-023-08150-6","article-title":"Proton pump inhibitors increase longitudinal risk of mortality, decompensation, and infection in cirrhosis: a meta-analysis","volume":"69","author":"Wong","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026061600251266000_bmjebm-2025-114134v1.35","doi-asserted-by":"crossref","unstructured":"Wu X , Zhang D , Yu Y , et al . Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Biosci Rep 2020;40. doi:10.1042\/BSR20193890","DOI":"10.1042\/BSR20193890"},{"key":"2026061600251266000_bmjebm-2025-114134v1.36","doi-asserted-by":"crossref","unstructured":"D\u2019Silva KM , Mehta R , Mitchell M , et al . Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect 2021. doi:10.1016\/j.cmi.2021.01.008","DOI":"10.1016\/j.cmi.2021.01.008"},{"key":"2026061600251266000_bmjebm-2025-114134v1.37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1089\/respcare.12397","article-title":"Ventilator-associated pneumonia in patients using proton pump inhibitors versus histamine H2 receptor antagonists: a systematic review and meta-analysis","volume":"70","author":"Alves Filho","year":"2025","journal-title":"Respir Care"},{"key":"2026061600251266000_bmjebm-2025-114134v1.38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00134-020-06209-w","article-title":"Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials","volume":"46","author":"Wang","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026061600251266000_bmjebm-2025-114134v1.39","doi-asserted-by":"crossref","unstructured":"Wu Z , Wu Y , Xiang Z , et al . The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials. Front Pharmacol 2025;16. doi:10.3389\/fphar.2025.1713256","DOI":"10.3389\/fphar.2025.1713256"},{"key":"2026061600251266000_bmjebm-2025-114134v1.40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/10600280211039240","article-title":"Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis","volume":"56","author":"Xun","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2026061600251266000_bmjebm-2025-114134v1.41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-021-03245-3","article-title":"Use of acid-suppressive drugs and risk of fracture in children and young adults: a meta-analysis of observational studies","volume":"78","author":"Yang","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1159\/000526122","article-title":"Relationship between proton pump inhibitors and adverse effects in hemodialysis patients: a systematic review and meta-analysis","volume":"47","author":"Zhang","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"2026061600251266000_bmjebm-2025-114134v1.43","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.4317\/medoral.27043","article-title":"Does the use of proton pump inhibitors lead to an increased risk of dental implant failure? A systematic review and meta-analysis","volume":"30","author":"Tang","year":"2025","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2026061600251266000_bmjebm-2025-114134v1.44","first-page":"28","article-title":"A meta-analysis of proton pump inhibitor exposure and the risk of adverse outcomes in patients with inflammatory bowel disease","volume":"43","author":"Zhang","year":"2025","journal-title":"Dig Dis"},{"key":"2026061600251266000_bmjebm-2025-114134v1.45","doi-asserted-by":"crossref","first-page":"108419","DOI":"10.1016\/j.reprotox.2023.108419","article-title":"Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations","volume":"119","author":"Peron","year":"2023","journal-title":"Reprod Toxicol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.46","doi-asserted-by":"crossref","unstructured":"Chen Y , Hu L , Sun C , et al . Will proton pump inhibitors increase the risk of diabetes mellitus? A systematic review and meta-analysis. Turk J Gastroenterol 2023. doi:10.5152\/tjg.2022.21480","DOI":"10.5152\/tjg.2022.21480"},{"key":"2026061600251266000_bmjebm-2025-114134v1.47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jgh.14789","article-title":"No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis","volume":"35","author":"Hussain","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.48","unstructured":"Zhang XY , Jia HL , Du L , et al . Meta-analysis of three kinds of proton pump inhibitors in the treatment of stress ulcer bleeding. In: Evaluation and analysis of drug-use in hospitals of China. 2020. Available: https:\/\/doi.org\/10.14009\/j.issn.1672-2124.2020.11.019"},{"key":"2026061600251266000_bmjebm-2025-114134v1.49","unstructured":"Mi XQ , Li SZ , Deng YJ , et al . Meta-analysis of the clinical efficacy and safety of proton pump inhibitors versus gastric mucosal protective agents in the treatment of laryngopharyngeal reflux disease. J Otolaryngol Ophthalmol Shandong Univ 2024. doi:10.6040\/j.issn.1673-3770.0.2024.491"},{"key":"2026061600251266000_bmjebm-2025-114134v1.50","doi-asserted-by":"crossref","DOI":"10.3390\/ph17060698","article-title":"Comparative efficacy and safety of potassium-competitive acid blockers vs proton pump inhibitors for peptic ulcer with or without Helicobacter pylori infection: a systematic review and network meta-analysis","volume":"17","author":"Ouyang","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026061600251266000_bmjebm-2025-114134v1.51","unstructured":"Ge L , Pan B , Pan JX , et al . An introduction of AMSTAR-2: a quality assessment instrument of systematic reviews including randomised or non-randomised controlled trials or both. Chin J Drug Eval 2017."},{"key":"2026061600251266000_bmjebm-2025-114134v1.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"2026061600251266000_bmjebm-2025-114134v1.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.03.017"},{"key":"2026061600251266000_bmjebm-2025-114134v1.55","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083864","article-title":"Core GRADE 4: rating certainty of evidence\u2014risk of bias, publication bias, and reasons for rating up certainty","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.56","unstructured":"Ryan R , Hill S . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, 2016. Available: http:\/\/cccrg.cochrane.org\/author-resources"},{"key":"2026061600251266000_bmjebm-2025-114134v1.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081905","article-title":"Core GRADE 3: rating certainty of evidence-assessing inconsistency","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.015"},{"key":"2026061600251266000_bmjebm-2025-114134v1.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.014"},{"key":"2026061600251266000_bmjebm-2025-114134v1.60","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081904","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026061600251266000_bmjebm-2025-114134v1.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.011"},{"key":"2026061600251266000_bmjebm-2025-114134v1.62","doi-asserted-by":"crossref","unstructured":"Wu B , Li D , Xu T , et al . Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep 2021;11. doi:10.1038\/s41598-021-83099-y","DOI":"10.1038\/s41598-021-83099-y"},{"key":"2026061600251266000_bmjebm-2025-114134v1.63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5500\/wjt.v9.i2.35","article-title":"Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis","volume":"9","author":"Boonpheng","year":"2019","journal-title":"WJT"},{"key":"2026061600251266000_bmjebm-2025-114134v1.64","doi-asserted-by":"crossref","unstructured":"Wo\u0142owiec \u0141 , Osiak-Gwiazdowska J , Ja\u015bniak A , et al . n.d. Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors. Front Pharmacol 16. doi:10.3389\/fphar.2025.1507812","DOI":"10.3389\/fphar.2025.1507812"},{"key":"2026061600251266000_bmjebm-2025-114134v1.65","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/jcm13071970","article-title":"Proton pump inhibitors and cancer risk: a comprehensive review of epidemiological and mechanistic evidence","volume":"13","author":"Sawaid","year":"2024","journal-title":"JCM"},{"key":"2026061600251266000_bmjebm-2025-114134v1.66","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001719","article-title":"Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective","volume":"12","author":"Brusselaers","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"2026061600251266000_bmjebm-2025-114134v1.67","doi-asserted-by":"crossref","DOI":"10.1177\/2042098618809927","article-title":"The risks of long-term use of proton pump inhibitors: a critical review","volume":"10","author":"Jaynes","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2026061600251266000_bmjebm-2025-114134v1.68","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.031"},{"key":"2026061600251266000_bmjebm-2025-114134v1.69","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s12325-023-02476-3","article-title":"Proton pump inhibitors, kidney damage, and mortality: an updated narrative review","volume":"40","author":"Edinoff","year":"2023","journal-title":"Adv Ther"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2025-114134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:25:43Z","timestamp":1781594743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2025-114134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":69,"alternative-id":["10.1136\/bmjebm-2025-114134"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2025-114134","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}